Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Daniel Wynn, MD

Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.Director, Clinical Research
Consultants In Neurology Ltd.
Member of the Healthcare Council

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic pain and migraine, epilepsy, Parkinson's disease, sleep disorders, attention deficit hyperactivity disorder (ADHD), and other neurologic diseases. Dr. Wynn serves on the Clinical Advisory Committee of National Multiple Sclerosis Society and is Co-Director of Consultants in Neurology Multiple Sclerosis Center. He is a member of numerous professional organizations including Alpha Omega Alpha Honor Medical Society, American Academy of Neurology, and American Medical Association. Dr. Wynn is widely published in The New England Journal of Medicine, Neurology, Annals of Neurology, Journal of the AMA, Pediatrics, Mayo Clinic Proceedings, and presents frequently at meetings in the US and overseas. (This is me - Update Profile)


Employment History
1988 - present Director, Clinical Research
Consultants In Neurology Ltd.

GLG Study Groups with Daniel Wynn, MD(?)

View All Study Groups with Daniel Wynn, MD

GLG NewsSM Analyses by Daniel Wynn, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Novartis and Multiple Sclerosis: A Major Commitment | 06-05-2008
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...

Abbott's ABT-089 --Much More than a Treatment for ADHD | 06-02-2008
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.

COPAXONE from the START of MS | 04-24-2008
Analysis of: Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS | www.pipelinereview.com
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Copaxone has become the leading treatment for relapsing remitting MS in the US.  The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.

Win for Talecris' Gamunex IVIG in Inflammatory Polyneuropathy | 02-15-2008
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP | pharmalive.com
Author: Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.

Talecris' form of IVIG, Gamunex was studied in the largest trial of IVIG in chronic inflammatory polyradiculoneuropathy (CIDP), with more than twice as many patients moving into remission.  CIDP is a common acquired autoimmune peripheral neuropathy, which if not treated, may lead to a peripheral...

View All GLG News SM Analyses by Daniel Wynn, MD

GLG InstituteSM Seminars with Daniel Wynn, MD(?)

 
Daniel Wynn, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Daniel Wynn, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics